TABLE 1 .
Cytokines showing significant differential gene expression in PBMCs of melioidosis patients compared to their expression in healthy negative controlsa
| Gene target | Description | Relative expression ratio (95% CI)b | P valuec |
|---|---|---|---|
| IL-1B | Interleukin-1 beta | 2.504 (1.229–5.100) | 0.0135 |
| IL-1RN | Interleukin-1 receptor antagonist | 1.62 (1.023–2.564) | 0.0403 |
| IL-8 | Interleukin-8 | 2.953 (1.394–6.257) | 0.0062 |
| IL-10 | Interleukin-10 | 2.257 (1.180–4.319) | 0.0158 |
| IL-27 | Interleukin-27 | 4.022 (1.632–9.915) | 0.0039 |
| INFA5 | Interferon alpha 5 | 0.189 (0.037–0.961) | 0.0454 |
| TNF | Tumor necrosis factor | 2.248 (1.082–4.670) | 0.0315 |
| CD40LG | CD40 ligand | 0.502 (0.336–0.752) | 0.002 |
| LTA | Lymphotoxin alpha | 0.327 (0.190–0.565) | 0.0003 |
| BMP6 | Bone morphogenetic protein 6 | 2.946 (1.470–5.904) | 0.007 |
| INHBA | Inhibin beta A | 6.07 (2.652–13.891) | 0.0002 |
| TGFB1 | Transforming growth factor beta 1 | 1.634 (1.121–2.383) | 0.0126 |
| PDGFA | Platelet-derived growth factor alpha polypeptide | 2.86 (1.444–5.667) | 0.0066 |
a
PBMCs, peripheral blood mononuclear cells. n = 26 melioidosis patients; n = 5 healthy negative controls.
b
A relative expression ratio of >1.5 indicates upregulation, and a relative expression ratio of ≤0.5 indicates downregulation in the experimental group compared to the expression in the control group. CI, confidence interval.
c
Gene targets are considered to show significant differential expression at a P value of <0.05.